Doctor Jorge Ortega-Hernandez

Back

Doctor Jorge Ortega-Hernandez

Instituto Nacional de Cardiologia Ignacio Chavez, Ciudad de Mexico (Mexico)

Member of:

Presentations

Time off target within the golden day: hemodynamic and metabolic variances in cardiogenic shock within the first 24 hours

Event: ESC Acute CardioVascular Care 2025

Topic: Cardiogenic Shock

Session: Cardiogenic shock unplugged: from risk stratification to rescue with mechanical circulatory support

Access

Is a pharmacoinvasive strategy in a middle-income country an effective alternative to cardiogenic shock? a single-center experience.

Event: ESC Acute CardioVascular Care 2025

Topic: Cardiogenic Shock

Session: Embracing diversity in intensive cardiac care

Access

International cooperation in cardiogenic shock is key to improving outcomes: Cardiogenic Shock Working Group impacts a single-center in a developing country.

Event: ESC Congress 2024

Topic: Cardiogenic Shock

Session: Modern views on worsening heart failure

Access

Focusing on women: dissecting sex-specific factors in cardiogenic shock through a large cohort and propensity score matching

Event: ESC Congress 2024

Topic: Cardiovascular Disease in Women

Session: Cardiovascular disease in women (3)

Access

Divergent hemometabolic dynamics: understanding the differences between acute myocardial infarction and heart failure related cardiogenic shock.

Event: ESC Congress 2024

Topic: Cardiogenic Shock

Session: Cardiogenic shock: international insights

Access

Addressing "immortal time bias" in the evaluation of treatment outcomes for post-infarction ventricular septal defect: implications for clinical practice and research

Event: ESC Congress 2023

Topic: Mechanical Complications

Session: Epidemiology in acute coronary syndromes (2)

Access

Higher number vasopressor usage linked to poorer outcomes despite obtaining hemodynamic goals in acute myocardial infarction complicated by cardiogenic shock

Event: ESC Congress 2023

Topic: Cardiogenic Shock

Session: Different aspects of acute coronary syndromes, myocardial infarction related cardiogenic shock and cardiac arrest

Access

Hemodynamic profiling: cardiac phenotypes and multiorgan organ failure in acute myocardial infarction with cardiogenic shock

Event: ESC Congress 2022

Topic: Cardiogenic Shock

Session: Cardiogenic shock

Access

Comparison of the prognostic performance of cardiogenic shock scores in a low-middle income country

Event: ESC Congress 2022

Topic: Cardiogenic Shock

Session: Acute cardiac care 1

Access

Utility of miR-155, miR-21 and miR-16 in plasma as biomarkers of atrial fibrillation

Event: ESC Congress 2021 - The Digital Experience

Topic: Noninvasive Diagnostic Methods

Session: Arrhythmias e-posters

Access

ESC 365 is supported by

Explore sponsored resources

Doctor Jorge Ortega-Hernandez Follow

Contributor content

Time off target within the golden day: hemodynamic and metabolic variances in cardiogenic shock within the first 24 hours

Is a pharmacoinvasive strategy in a middle-income country an effective alternative to cardiogenic shock? a single-center experience.

International cooperation in cardiogenic shock is key to improving outcomes: Cardiogenic Shock Working Group impacts a single-center in a developing country.

Focusing on women: dissecting sex-specific factors in cardiogenic shock through a large cohort and propensity score matching

Divergent hemometabolic dynamics: understanding the differences between acute myocardial infarction and heart failure related cardiogenic shock.

Addressing "immortal time bias" in the evaluation of treatment outcomes for post-infarction ventricular septal defect: implications for clinical practice and research

Higher number vasopressor usage linked to poorer outcomes despite obtaining hemodynamic goals in acute myocardial infarction complicated by cardiogenic shock

Hemodynamic profiling: cardiac phenotypes and multiorgan organ failure in acute myocardial infarction with cardiogenic shock

Comparison of the prognostic performance of cardiogenic shock scores in a low-middle income country

Utility of miR-155, miR-21 and miR-16 in plasma as biomarkers of atrial fibrillation

ESC 365 is supported by

Doctor Jorge Ortega-Hernandez